Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- ANNALS OF HEMATOLOGY91(4) · pp.543 · 2012
- 피인용
- Web of Science 48
- JCR IF
- JCR 2011 2.615
- ISSN
- 0939-5555
저자
- Kang, Hye Jin국립암센터, Korea Inst Radiol & Med Sci, Dept Internal Med, KO
- Kim, Won Seog성균관대학교, Sch Med, Samsung Med Ctr, KO
- Kim, Seok Jin성균관대학교, Sch Med, Samsung Med Ctr, KO
- Lee, Je-Jung전남대학교, Hwasun Hosp, Dept Hematol Oncol, KO
- Yang, Deok-Hwan전남대학교, Hwasun Hosp, Dept Hematol Oncol, KO
- Kim, Jin Seok연세대학교, Coll Med, Dept Internal Med, KO
- Lee, Se-Ryeon고려대학교, Dept Internal Med, Sch Med, KO
- Lee, Gyeong-Won경상대학교, Sch Med, Dept Internal Med, KO
- Kim, Hyo Jung한림대학교, Sacred Heart Hosp, Hallym Med Ctr, KO
- Kim, Ho Young한림대학교, Sacred Heart Hosp, Hallym Med Ctr, KO
- Oh, Sung Yong동아대학교, Coll Med, Dept Internal Med, KO
- Kim, Hugh Chul아주대학교, Dept Internal Med, KO
- Eom, Hyeon-Seok국립암센터, Res Inst & Hosp, Hematol Oncol Clin, KO
- 정주섭부산대학교, 의과대학, 의과학과, KO
- Park, Jinny가천대학교, Dept Internal Med, KO
- Suh, Cheolwon울산대학교, Coll Med, Dept Oncol, KO
- Ryoo, Baek-Yeol국립암센터, Korea Inst Radiol & Med Sci, Dept Internal Med, KO
초록
We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2) and vincristine 1.4 mg/m(2) (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
키워드
CVPFirst-lineImmunochemotherapyMarginal zone lymphomaRituximabB-CELL LYMPHOMAANTI-CD20 MONOCLONAL-ANTIBODYNON-HODGKINS-LYMPHOMAADVANCED FOLLICULAR LYMPHOMATISSUE LYMPHOMAMALT TYPECHOP CHEMOTHERAPYFLUDARABINE PHOSPHATECLINICAL PRESENTATIONORAL FLUDARABINE
식별자
- WoS UID
- 000301243600009



로그인
연구물 목록으로